ETON Quote, Financials, Valuation and Earnings

Oragenics, Inc. has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of --. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Oragenics, Inc.'s return on equity of -509.23%.

Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 81.05%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.07%. Given that Oragenics, Inc. has higher upside potential than Eton Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than Eton Pharmaceuticals, Inc..

Eton Pharmaceuticals, Inc. has a beta of 1.172, which suggesting that the stock is 17.166% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than Oragenics, Inc. quarterly revenues of --. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 6.29x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of --. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Palatin Technologies's return on equity of --.

Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 81.05%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Eton Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Eton Pharmaceuticals, Inc..

Eton Pharmaceuticals, Inc. has a beta of 1.172, which suggesting that the stock is 17.166% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than Palatin Technologies quarterly revenues of --. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Palatin Technologies's net income of --. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 6.29x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sanara MedTech, Inc. has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of 3.17%. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Sanara MedTech, Inc.'s return on equity of -20.48%.

Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 81.05%. On the other hand Sanara MedTech, Inc. has an analysts' consensus of $41.00 which suggests that it could grow by 63.74%. Given that Eton Pharmaceuticals, Inc. has higher upside potential than Sanara MedTech, Inc., analysts believe Eton Pharmaceuticals, Inc. is more attractive than Sanara MedTech, Inc..

Eton Pharmaceuticals, Inc. has a beta of 1.172, which suggesting that the stock is 17.166% more volatile than S&P 500. In comparison Sanara MedTech, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.199%.

Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sanara MedTech, Inc. pays out -- of its earnings as a dividend.

Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are smaller than Sanara MedTech, Inc. quarterly revenues of $26.3M. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is lower than Sanara MedTech, Inc.'s net income of $834.5K. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Sanara MedTech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 6.29x versus 2.11x for Sanara MedTech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of --. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 81.05%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3528.82%. Given that Theriva Biologics, Inc. has higher upside potential than Eton Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Eton Pharmaceuticals, Inc..

Eton Pharmaceuticals, Inc. has a beta of 1.172, which suggesting that the stock is 17.166% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 6.29x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.